Home
Diseases
NPC
News

News Related to NPC

Related coverage linked through entity extraction aliases.

Junshi Biosciences Reports 28% Revenue Growth in 2025; Absci Schedules Q4 Results

Mar 13, 2026

Junshi Biosciences reported total revenue of approximately RMB2,498 million in 2025, a 28% increase year-over-year, driven by toripalimab sales growth. Absci Corporation announced it will report fourth quarter and full year 2025 financial results on March 24, 2026.

FDA Accepts NDAs for Beren's Adrabetadex and Dr. Reddy's Abatacept Biosimilar

Feb 23, 2026

The FDA has accepted for review Beren Therapeutics' NDA for adrabetadex in infantile-onset Niemann-Pick disease type C with a PDUFA date of August 17, 2026, and Dr. Reddy's BLA for a biosimilar to Orencia (abatacept).